Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 11.3% in the afternoon session after documents revealed that advisers to the U.S. Food and Drug Administration (FDA) will weigh ...

Novavax has had an impressive run over the past six months as its shares have beaten the S&P 500 by 27.6%. The stock now ...

Vaccine biotechnology company Novavax (NASDAQ:NVAX) beat Wall Street’s revenue expectations in Q1 CY2026, but sales fell by 79.1% year on year to $139.5 million. Its GAAP loss of $0.06 per share was ...

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...

On Thursday, Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the consensus of $343.85 million. Higher product sales for the ...

Novavax on Wednesday beat Wall Street estimates for first-quarter revenue, as upfront and milestone payments from vaccine supply and licensing deals helped offset pressure ​from sagging demand, ...

Novavax, Inc. (NASDAQ:NAVX) stock traded higher on Wednesday. In an SEC filing, Novavax said, “We believe that our Biologics License Application (BLA) is approvable based on conversations with U.S.

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.